12-003
Showing 1 - 25 of >10,000
LMV-12 Combined With Osimertinib in NSCLC
Not yet recruiting
- Non Small Cell Lung Cancer
- LMV-12(HE003) and Osimertinib
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Oct 25, 2023
Cutaneous T-cell Lymphoma (CTCL) Trial in United Kingdom (CDK-003)
Recruiting
- Cutaneous T-cell Lymphoma (CTCL)
- CDK-003
-
Birmingham, United Kingdom
- +3 more
Apr 22, 2022
Seasonal Allergic Rhinitis Trial in China (LP-003 dose 1, LP-003 dose 2, Placebo)
Recruiting
- Seasonal Allergic Rhinitis
- LP-003 dose 1
- +2 more
-
Beijing, Beijing, China
- +16 more
Sep 18, 2023
Metastatic Colorectal Cancer Trial in Worldwide (RO7122290, Cibisatamab, Obinutuzumab)
Recruiting
- Metastatic Colorectal Cancer
- RO7122290
- +2 more
-
Toronto, Ontario, Canada
- +15 more
Jan 13, 2023
Sickle Cell Disease (SCD) Trial in Worldwide (Crizanlizuamb, Standard of Care)
Active, not recruiting
- Sickle Cell Disease (SCD)
- Crizanlizuamb
- Standard of Care
-
Birmingham, Alabama
- +24 more
Jan 12, 2023
Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer Trial in Worldwide (Patient outreach,
Active, not recruiting
- Locally Advanced or Metastatic Medullary Thyroid Cancer
- Medullary Thyroid Cancer
- Patient outreach
- Vandetanib
-
St Leonards, Australia
- +33 more
Oct 20, 2021
Healthy, Safety and Tolerability Trial in Cypress (DF-003, Placebo)
Recruiting
- Healthy
- Safety and Tolerability
- DF-003
- Placebo
-
Cypress, CaliforniaAltasciences Clinical Los Angeles, Inc
Aug 9, 2023
Breast Cancer Trial in Worldwide (Trastuzumab Deruxtecan)
Recruiting
- Breast Cancer
- Trastuzumab Deruxtecan
-
San Diego, California
- +90 more
Jul 19, 2022
Chronic Hepatitis B and Hepatitis D Co-infection Trial in Changchun (HH-003 20mg/kg, HH-003 3mg/kg)
Active, not recruiting
- Chronic Hepatitis B and Hepatitis D Co-infection
- HH-003 20mg/kg
- HH-003 3mg/kg
-
Changchun, Jilin, ChinaFirst Hospital of Jilin University
Dec 30, 2022
Treatment Resistant Depression Trial in New York (BPL-003)
Not yet recruiting
- Treatment Resistant Depression
-
New York, New YorkNew York State Psychiatric Institute
May 12, 2023
Congenital Pseudarthrosis of Tibia Trial in Baltimore, Brussels (NVD-003, an autologous 3D scaffold free osteogenic graft)
Recruiting
- Congenital Pseudarthrosis of Tibia
- NVD-003, an autologous 3D scaffold free osteogenic graft
-
Baltimore, Maryland
- +1 more
Jan 11, 2023
Autism Spectrum Disorder Trial in Staten Island (ML-004 (IR)/(ER) tablet)
Recruiting
- Autism Spectrum Disorder
- ML-004 (IR)/(ER) tablet
-
Staten Island, New YorkRichmond Behavioral Associates
Jun 1, 2023
Acute Ischemic Stroke Trial (exosomes derived from human induced pluripotent stem cell for injection, a of exosomes derived
Not yet recruiting
- Acute Ischemic Stroke
- exosomes derived from human induced pluripotent stem cell for injection
- a placebo of exosomes derived from human induced pluripotent stem cell for injection
- (no location specified)
Nov 15, 2023
Coronavirus Disease 2019 Trial in Santiago (Interferon-Alpha2B, Placebo)
Completed
- Coronavirus Disease 2019
- Interferon-Alpha2B
- Placebo
-
Santiago, RM, ChileRed de Salud UC Christus
Aug 3, 2022
Treatment Resistant Depression Trial in London (BPL-003)
Not yet recruiting
- Treatment Resistant Depression
-
London, United Kingdom
- +1 more
Dec 13, 2022
Alcohol Use Disorder Trial in London (BPL-003)
Not yet recruiting
- Alcohol Use Disorder
-
London, United KingdomKing's College London
Dec 21, 2022
Diabetic Peripheral Neuropathy Trial in United States (Engensis, Placebo)
Recruiting
- Diabetic Peripheral Neuropathy
- Engensis
- Placebo
-
Phoenix, Arizona
- +15 more
Nov 3, 2022
ISS T-003 Trial Volunteers (ISS T-003 EF-UP2020)
Not yet recruiting
- HIV Infections
- (no location specified)
Jan 9, 2023
Rett Syndrome Trial in Australia, Canada, United Kingdom (ANAVEX2-73 oral liquid, Placebo oral liquid)
Recruiting
- Rett Syndrome
- ANAVEX2-73 oral liquid
- Placebo oral liquid
-
Sydney, New South Wales, Australia
- +11 more
Jan 31, 2023
Chronic Myeloid Leukemia Trial in Worldwide (Omacetaxine mepesuccinate)
Completed
- Chronic Myeloid Leukemia
- Omacetaxine mepesuccinate
-
Los Angeles, California
- +31 more
Nov 11, 2021